Markets Stocks Economy Crypto Earnings Banking Energy
Home› Markets› Feature
Markets · Exclusive

Gold edges up as Treasury yields slip again ahead of Fed meeting

Gold edges up as Treasury yields slip again ahead of Fed meeting
Markets · 2026
Photo · Eleanor Whitfield for Daily Digest Invest
By Eleanor Whitfield Markets Editor-in-Chief Oct 21, 2026 3 min read

Gold prices inched higher on Tuesday, recovering from a near one-week low, as U.S. Treasury yields slipped for a second straight session. The move comes as investors position ahead of the Federal Reserve's next policy meeting and a key inflation reading.

Spot gold rose 0.3% to $4,137.94 per ounce, while the 10-year Treasury yield fell again. The relationship between the two is central to gold's recent moves: because gold pays no interest, its appeal tends to rise when yields on income-paying assets like bonds fall.

Why yields matter for gold

When Treasury yields drop, the opportunity cost of holding gold declines. In plain terms, investors are giving up less potential income by parking money in a metal that doesn't pay a coupon. That dynamic has been the main driver behind gold's modest gains this week.

The yield on the 10-year Treasury has been volatile recently, influenced by a mix of economic data, inflation expectations, and shifts in investor sentiment. Treasury yields eased to 5.102% earlier as AI-related stock jitters fueled safe-haven demand, and similar forces appear to be at play now.

But the bigger picture is that yields remain relatively elevated compared with recent years. That has kept a lid on gold's upside, even as geopolitical and economic uncertainties support the metal as a store of value.

What investors are watching next

The market is in a waiting game. Traders are pricing in an 88% chance that the Fed will raise interest rates again in December, according to the brief. That expectation is a key reason gold hasn't rallied more sharply.

Higher interest rates tend to weigh on gold because they boost the dollar and increase the yield on cash and bonds, making non-yielding assets less attractive. With a December hike largely priced in, gold's near-term path may depend on whether the Fed signals a pause or a continued tightening cycle.

Two events loom large on the calendar: the Fed's October 27-28 meeting and the next personal consumption expenditures (PCE) inflation report. PCE is the Fed's preferred inflation gauge, and a hotter-than-expected reading could reinforce the case for another hike, pressuring gold. A cooler number could ease those fears and give the metal a boost.

As the dollar slipped as oil and yields eased, gold found some support. A weaker dollar makes gold cheaper for overseas buyers, which can lift demand.

What it means for everyday investors

For ordinary investors, gold's recent moves are a reminder of how sensitive the metal is to interest rate expectations. Small daily changes in yields can nudge gold up or down, but the broader trend is shaped by the Fed's policy path.

If you hold gold as part of a diversified portfolio, you're likely watching the same signals as professional traders: the Fed's tone, inflation data, and the direction of real yields (yields adjusted for inflation). When real yields fall, gold tends to shine; when they rise, it often struggles.

It's also worth noting that gold's price action this week has been relatively muted. That suggests the market is waiting for more clarity before making big bets. The Fed meeting and PCE report could provide that clarity, so expect potentially larger swings in gold prices around those events.

As always, gold is not a one-way bet. It can serve as a hedge against uncertainty, but it doesn't generate income, and its price can be volatile. Investors should consider how gold fits into their broader financial picture rather than reacting to day-to-day moves.

For now, the metal is holding its ground, but the real test may come later this week when the Fed speaks and inflation data lands.

More from this story

Next article · Don't miss

Alcon's $550M Neurotech Deal Adds $250K Retina Implant

Alcon is buying Neurotech Pharmaceuticals for $550 million to add Encelto, a retina implant for a rare eye disease. A new billing code could help turn the niche treatment into a steady revenue stream.

Read the story →
Alcon's $550M Neurotech Deal Adds $250K Retina Implant